Abstract 5262
Background
ICI is a standard of care in R/M HNSCC pts progressing to platinum compounds. However, few pts respond to ICI and irAEs could limit their use.There are contradictory reports regarding the association of irAEs and outcomes to ICI. The aim of this study is to further evaluate the potential impact of irAEs on outcomes for HNSCC.
Methods
We performed a retrospective observational study based on all R/M HNSCC pts treated by ICI in our center during 2014-19. To limit the bias due to the association between ICI administration duration, obtention of objective response (OR) and occurrence of irAE, a Landmark analysis method with 90 days (d) cut-off was used.
Results
We included 103 R/M HNSCC pts (80% male, 73% smokers). Primary tumor locations were: oropharynx (42%), oral cavity (23%), hypopharynx (18%) and larynx (17%). ICI were administered as monotherapy (43%) or combination (57%; CTLA-4 inhibitor, ICOS agonist). There were 14 responders (R) with median time to obtain OR of 102 d (8 after 90 d). Median ICI duration was 376 d in R pts and 84 d in others. irAEs were observed in 38 pts (37%), with low frequency of grade (G) 3-4 (6%). Occurrence of irAEs within the first 90 d (named early AEs) was observed in 25 pts (24%). 51 pts (50%) remained on ICI beyond 90 d, including all the 14 R: 30 pts (59%) had irAEs and 17 (33%) had early irAEs. In total cohort, OR was more frequent in pts with any irAE (32%) than in others (3%). Results were similar with irAE G2-4: 42% OR vs 5% OR. But, using landmark method, in pts who received ≥ 90 d ICI, this association was no longer observed: 35% of pts with early irAEs had OR vs 24% in other pts (p = 0.37), and 36% vs 25% for early irAEs of G2-4 (p = 0.47). Median [95%CI] PFS and OS were 3.6 months (m) [2.9-4.5] and 10.6m [7.6-13.2] in total cohort; 5.8 m [4.8-7.7] and 19.1 m [12.6-32.5] in ICI ≥90 d. Early irAEs were not associated with PFS or OS in this latter subgroup.
Conclusions
The impact of irAEs on outcomes could be mistaken if not taking into consideration the ICI duration because the likelihood of irAEs and OR increases with treatment duration. Using a Landmark analysis with 90 d cut-off, we did not observe an association between irAEs and outcome in R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Baste Rotllan: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol Meyers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Nanobiotix; Honoraria (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (institution): PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract